US Patent Issued to Praxis Precision Medicines on Feb. 17 for "Process for making (3-[cyclopropylethoxy(difluoro)methyl-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl- [1,2,4triazolo[4,3-apyrazine" (Canadian, American Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,797, issued on Feb. 17, was assigned to Praxis Precision Medicines Inc. (Boston).

"Process for making (3-[cyclopropylethoxy(difluoro)methyl-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl- [1,2,4triazolo[4,3-apyrazine" was invented by Gabriel Martinez Botella (Wayland, Mass.) and Andrew Mark Griffin (L'lle Bizard, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to, in part, a method of making (3-[cyclopropylethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridyl]-[1,2,4]triazolo[4,3-Alpha]pyrazine (Compound 1);comprising reacting key synthetic intermediates and providing methods of making the s...